Status Dystonicus, Oculogyric Crisis and Paroxysmal Dyskinesia in a 25 Year-Old Woman with a Novel KCNMA1 Variant, K457E

Tremor Other Hyperkinet Mov (N Y). 2020 Oct 27:10:49. doi: 10.5334/tohm.549.

Abstract

The diagnosis of a paroxysmal dyskinesia is difficult and status dystonicus is a rare life threatening movement disorder characterised by severe, frequent or continuous episodes of dystonic spasms. A 25 year old woman with chronic ataxia and paroxysmal dyskinesia presented with facial twitching, writhing of arms, oculogyric crisis and visual and auditory hallucinations. She developed respiratory failure and was ventilated. No cause was found so whole exome sequencing was performed and this revealed a novel, non-synonymous heterozygous variant in exon 11 of the KCNMA1 gene, K457E (c 1369A>G) in the patient but not her parents. This variant has not been previously reported in gnomAD or ClinVar. The finding of a de novo variant in a potassium channel gene guided a trial of the potassium channel antagonist 3,4 diaminopyridine resulting in significant improvement, discharge from the intensive care unit and ultimately home.

Keywords: BK channel; Dyskinesia; Dystonia; Genetics; KCa1.1; Movement disorders; Neurological Emergency; PNKD3; Seizure; calcium-activated potassium channel.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Video-Audio Media

MeSH terms

  • Adult
  • Amifampridine / therapeutic use
  • Ataxia / drug therapy
  • Ataxia / genetics*
  • Ataxia / physiopathology
  • Chorea / drug therapy
  • Chorea / genetics*
  • Chorea / physiopathology
  • Dystonia / drug therapy
  • Dystonia / genetics*
  • Dystonia / physiopathology
  • Electroencephalography
  • Female
  • Hallucinations / drug therapy
  • Hallucinations / genetics*
  • Hallucinations / physiopathology
  • Humans
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / genetics*
  • Ocular Motility Disorders / drug therapy
  • Ocular Motility Disorders / genetics*
  • Ocular Motility Disorders / physiopathology
  • Potassium Channel Blockers / therapeutic use

Substances

  • KCNMA1 protein, human
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
  • Potassium Channel Blockers
  • Amifampridine